Annexon, Inc. (ANNX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript
Annexon Q2 Earnings Call Highlights
Annexon NASDAQ: ANNX said it expanded its pivotal ARCHER II trial of vonaprument in geographic atrophy, adding an independent 24-month dual primary endpoint alongside the study's existing 15-month primary endpoint. The company said it remains confident in a planned fourth-quarter assessment of the 15-month endpoint while seeking to capture longer-term efficacy data for a potential product label.
Annexon: Perfect Complement To A Speculative Biotech Portfolio
Annexon remains a high-risk/high-reward Buy, driven by two near-term blockbuster therapies, notably tanruprubart for Guillain-Barré syndrome (GBS). Tanruprubart achieved highly significant Phase 3 results, with a 2.4-fold GBS-DS improvement versus placebo and strong safety, positioning it for standard-of-care status. Regulatory filings are underway: MAA was submitted to EMA, with FDA BLA planned for 2026, supported by ongoing FORWARD and real-world evidence studies.
Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Annexon, Inc. (ANNX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Annexon Eyes ‘Win Season' With Q4 Vision Trial Data, GBS Filings Ahead
Annexon NASDAQ: ANNX executives used a Goldman Sachs Healthcare Conference session to outline the company's upcoming clinical and regulatory catalysts, led by pivotal Phase III data expected in the fourth quarter for vonaprument in geographic atrophy, a form of advanced dry age-related macular degeneration.
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout
Annexon NASDAQ: ANNX executives outlined a series of expected clinical and regulatory updates across the company's complement-focused pipeline during a session at the Jefferies Conference, highlighting programs in geographic atrophy, Guillain-Barré syndrome and cold agglutinin disease.
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference
Annexon NASDAQ: ANNX President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a presentation at the Bank of America Healthcare Conference, highlighting upcoming data in geographic atrophy and regulatory filings for Guillain-Barré syndrome.
Annexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Annexon, Inc. (ANNX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?
The mean of analysts' price targets for Annexon (ANNX) points to a 165.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases
Annexon offers high-risk, high-reward potential with its C1q-targeted pipeline, led by tanruprubart for GBS and vonaprument for geographic atrophy. Tanruprubart's Phase III results are promising, but there is U.S. regulatory uncertainty due to non-U.S. trial sites and dose-response questions. Vonaprument's Phase III trial focuses on vision preservation, potentially differentiating ANNX in the competitive but large geographic atrophy market.
Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy
Annexon Inc. (ANNX) is still a "Buy" in my view, driven by progress in its c1q inhibitor pipeline for rare diseases. ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA discussions. Vonaprument, targeting dry age-related macular degeneration patients with geographic atrophy, is in phase 3 testing with topline data expected in 2nd half of 2026.
